Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women.

Shah DK, Missmer SA, Correia KF, Ginsburg ES.

J Clin Endocrinol Metab. 2014 Apr;99(4):1314-21. doi: 10.1210/jc.2013-4086. Epub 2014 Jan 29.

2.

Bioavailability of hCG after intramuscular or subcutaneous injection in obese and non-obese women.

Chan CC, Ng EH, Chan MM, Tang OS, Lau EY, Yeung WS, Ho PC.

Hum Reprod. 2003 Nov;18(11):2294-7.

PMID:
14585876
3.

Pharmacodynamics and pharmacokinetics after subcutaneous and intramuscular injection of human chorionic gonadotropin.

Saal W, Glowania HJ, Hengst W, Happ J.

Fertil Steril. 1991 Aug;56(2):225-9.

PMID:
1712735
6.

Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome.

Rosencrantz MA, Coffler MS, Haggan A, Duke KB, Donohue MC, Shayya RF, Su HI, Chang RJ.

J Clin Endocrinol Metab. 2011 Apr;96(4):1106-13. doi: 10.1210/jc.2010-2200. Epub 2011 Jan 26.

7.

Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction.

Araujo E Jr, Bernardini L, Frederick JL, Asch RH, Balmaceda JP.

J Assist Reprod Genet. 1994 Feb;11(2):74-8.

PMID:
7819706
9.

Subcutaneous versus intramuscular administration of human chorionic gonadotropin during an in vitro fertilization cycle.

Stelling JR, Chapman ET, Frankfurter D, Harris DH, Oskowitz SP, Reindollar RH.

Fertil Steril. 2003 Apr;79(4):881-5.

PMID:
12749424
10.

Ovarian age-related responsiveness to human chorionic gonadotropin in women with polycystic ovary syndrome.

Piltonen T, Koivunen R, Perheentupa A, Morin-Papunen L, Ruokonen A, Tapanainen JS.

J Clin Endocrinol Metab. 2004 Aug;89(8):3769-75.

PMID:
15292303
13.

Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin.

Koivunen RM, Morin-Papunen LC, Ruokonen A, Tapanainen JS, Martikainen HK.

Hum Reprod. 2001 Dec;16(12):2546-51.

PMID:
11726572
14.

Disappearance of exogenously administered human chorionic gonadotropin.

Damewood MD, Shen W, Zacur HA, Schlaff WD, Rock JA, Wallach EE.

Fertil Steril. 1989 Sep;52(3):398-400.

PMID:
2776893
15.
16.
17.

Short-term human chorionic gonadotropin-induced testosterone rise does not modify leptin levels in eugonadal men.

Panidis D, Koliakos G, Kourtis A, Rousso D, Mavromatidis G, Triantos A, Kalahanis I.

Gynecol Endocrinol. 2002 Feb;16(1):75-81.

PMID:
11915586
18.

Ovulation after intravenous and intramuscular human chorionic gonadotropin.

Fischer RA, Nakajima ST, Gibson M, Brumsted JR.

Fertil Steril. 1993 Sep;60(3):418-22.

PMID:
8375519
19.

Human chorionic gonadotropin (HCG) treatment of obesity.

Shetty KR, Kalkhoff RK.

Arch Intern Med. 1977 Feb;137(2):151-5.

PMID:
836112
20.

Pharmacokinetics and pharmacodynamics of human chorionic gonadotropin (hCG) after rectal administration of hollow-type suppositories containing hCG.

Kowari K, Hirosawa I, Kurai H, Utoguchi N, Fujii M, Watanabe Y.

Biol Pharm Bull. 2002 May;25(5):678-81.

Supplemental Content

Support Center